Monopar Therapeutics Stock
Monopar Therapeutics Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Chandler D. Robinson
- Employees
- 22
- Market cap
- $465 M
- IPO
- 19/12/2019
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated…
Monopar Therapeutics stock: price history
1D
-3.5%
1W
-12.3%
1M
-31.7%
6M
+23.2%
YTD
+6.1%
1Y
-16.1%
2Y
+1,216.9%
5Y
+182.2%
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~9% stronger price swings than usual
Monopar Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology therapeutics. Its portfolio includes various drug candidates such as ALXN1840 for the treatment of Wilson disease as well as MNPR-101 and its variants for treating solid tumors through radiopharmaceuticals. The company is in the clinical development phase and leverages partnerships with organizations such as NorthStar, Excel Diagnostics and Nuclear Oncology Center as well as licensing agreements with Alexion to advance the development and commercialization of its therapeutic approaches.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Monopar Therapeutics
Analyst assessment of Monopar Therapeutics
PRICE TARGET LOW
US$105.00
CONSENSUS
US$126.00
MEDIAN
US$125.00
PRICE TARGET HIGH
US$145.00
0
STRONG BUY
11
BUY
3
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 11/09/2026
Monopar Therapeutics stock metrics
P/E
-29.6
P/B
4.52
EV/EBITDA
-22.29
RETURN ON EQUITY
-4.1%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
58.7%
FLOAT SHARES
3,937,990
AVG. DAILY VOLUME (30D)
153,703
Insider transactions (SEC)
STARR CHRISTOPHER M
STARR CHRISTOPHER M
STARR CHRISTOPHER M
STARR CHRISTOPHER M
Cittadine Andrew
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Monopar Therapeutics stock
What does Monopar Therapeutics do?
Monopar Therapeutics Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Chandler D. Robinson, the company employs around 22 people.
The IPO was on 19/12/2019; the stock trades on NASDAQ under the ticker MNPR.
What do analysts say about Monopar Therapeutics stock?
14 analysts rate the stock, the consensus is Buy (as of 11/09/2026).
The average price target is US$126.00, ranging from US$105.00 to US$145.00, with a median of US$125.00.
This is an external assessment, not a statement by Market Jury.
When does Monopar Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly 9% stronger than usual.
Does Monopar Therapeutics pay a dividend?
No, Monopar Therapeutics currently does not pay a dividend.
Which stocks are comparable to Monopar Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Monopar Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Monopar Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.